GSK’s ViiV Healthcare HIV-focused podcast is back by popular demand for a second season.
“Being Seen” delves even deeper into topics that matter to the HIV, Black, gay and queer community, which is disproportionately affected by HIV, in the second season of the now Clio-award winning podcast. The new series is again hosted and co-produced by award-winning writer and activist Darnell Moore and agency Harley & Co.
The podcast, which reached second place on Apple’s new and noteworthy list, addresses the inequities of HIV for the Black community.
While treatments are available to control the epidemic—from medicines that essentially stop transmission to drugs for prevention—there is more to the show than discussions on drugs, Marc Meachem, ViiV’s head of external affairs for North America, said.
“We’ve got the science down, but in order to address it and to disrupt the disparities, we’ve got to deal with the human element, and we’ve got to reach people in a different way,” he said.
The new season of 11 episodes launched this month and once again highlights important voices in the community, this time taking on topics including fatherhood, mental heath and sports. The just-released second episode discusses mentorship and features writer, actor and producer Lena Waithe as co-host.
In addition to social media publicity, word of mouth is the key driver in the show’s popularity, Meachem said. He’s noticed that many of the people who took part in the first series are now promoting the second one through their social networks.
“I think this is beyond entertainment, this is a real dialogue,” he said.
Meachem added, “If there’s one message I want to get out to people is that 30 years from now, we don’t have to talk about how we still haven’t ended the epidemic for people of color. We can do this. It does require a whole society approach and that does involve us, it does involve experts and those who have power in society to engage with the people who are facing the issues, and to listen to them and then to involve them in our own solutions.”
ViiV’s portfolio of HIV meds continues to grow. In January, the FDA approved Cabenuva, the first long-acting, injectable HIV regimen for patients who are already virologically suppressed. Instead of a daily pill, like most antiretroviral medications, Cabenuva is injected once a month. ViiV’s other meds include two-drug regimens Dovato and Juluca.
by Sharon Klahr Coey
This year has already witnessed a handful of memorable FDA approvals. But the race isn’t over yet. Looking to close out 2021 with FDA approvals stand four potential blockbusters from the likes of Argenx, UCB, Pfizer and Roche, according to Evaluate Pharma. Those meds combined are worth roughly $7.1 billion in sales cumulatively by 2026, according to Evaluate’s estimates.
Getting started is often the most difficult part—and that’s especially true in rare diseases and diagnoses. Patients and families often spend many years searching for their diagnosis starting point. For Horizon Therapeutics’ first innovation challenge, it took that struggle to heart and asked for technology-based rare disease solutions that result in faster or more accurate diagnoses.
Researchers from the Quadram Institute and the University of East Anglia (UEA) discovered that treating mice with broad-spectrum antibiotics increased the rate at which their breast cancer tumours grew.